539 related articles for article (PubMed ID: 32925186)
1. Advances in chimeric antigen receptor T cells.
Beyar-Katz O; Gill S
Curr Opin Hematol; 2020 Nov; 27(6):368-377. PubMed ID: 32925186
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
Levin A; Shah NN
Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
[TBL] [Abstract][Full Text] [Related]
3. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
Reagan PM; Friedberg JW
Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
[TBL] [Abstract][Full Text] [Related]
4. The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
Nair R; Neelapu SS
Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
Westin JR; Kersten MJ; Salles G; Abramson JS; Schuster SJ; Locke FL; Andreadis C
Am J Hematol; 2021 Oct; 96(10):1295-1312. PubMed ID: 34310745
[TBL] [Abstract][Full Text] [Related]
6. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
[TBL] [Abstract][Full Text] [Related]
7. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
Al-Juhaishi T; Ahmed S
Curr Hematol Malig Rep; 2021 Feb; 16(1):32-39. PubMed ID: 33630232
[TBL] [Abstract][Full Text] [Related]
8. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
Huang H; Wu HW; Hu YX
J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
[TBL] [Abstract][Full Text] [Related]
9. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
10. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Chow VA; Shadman M; Gopal AK
Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
Abramson JS
Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
[TBL] [Abstract][Full Text] [Related]
12. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
Nakazawa Y
Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
[TBL] [Abstract][Full Text] [Related]
13. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
Braendstrup P; Levine BL; Ruella M
Cytotherapy; 2020 Feb; 22(2):57-69. PubMed ID: 32014447
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma.
Ghobadi A
Curr Res Transl Med; 2018 May; 66(2):43-49. PubMed ID: 29655961
[TBL] [Abstract][Full Text] [Related]
15. CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas.
Ahmad A; Uddin S; Steinhoff M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486160
[TBL] [Abstract][Full Text] [Related]
16. [Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
Beauvais D; Bachy E; Baruchel A; Bay JO; Caillot D; Cartron G; Damaj G; Furst S; Le Gouill S; Morschhauser F; Rabian F; Rubio MT; Thieblemont C; Yakoub-Agha I
Bull Cancer; 2021; 108(7-8):725-729. PubMed ID: 33423776
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
18. [Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma].
Hanajiri R; Furukawa K; Nakashima M; Ushijima Y; Shimada K; Ishikawa Y; Terakura S; Murata M; Kiyoi H
Rinsho Ketsueki; 2023; 64(3):167-174. PubMed ID: 37019669
[TBL] [Abstract][Full Text] [Related]
19. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
[TBL] [Abstract][Full Text] [Related]
20. Engineered T Cells: CAR T Cell Therapy and Beyond.
Johnson PC; Abramson JS
Curr Oncol Rep; 2022 Jan; 24(1):23-31. PubMed ID: 35059997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
